目的 觀察阿加曲班治療頻發(fā)短暫性腦缺血發(fā)作的療效。方法 選取2019年1月—2021年1月在天津市寧河區(qū)醫(yī)院治療的68例頻發(fā)短暫性腦缺血發(fā)作患者，隨機(jī)分為對(duì)照組（34例）和治療組（34例）。對(duì)照組靜脈滴注注射用血塞通，400 mg加入生理鹽水500 mL，1次/d，每次滴注時(shí)間>3 h。治療組靜脈滴注阿加曲班注射液，60 mg溶入生理鹽水500 mL持續(xù)滴注24 h，連續(xù)2 d，此后5 d以10 mg加入生理鹽水250 mL滴注，2次/d，每次滴注時(shí)間>3 h，2次間隔>8 h。兩組治療7 d。觀察兩組患者臨床療效，比較治療前后兩組患者腦梗死轉(zhuǎn)化和神經(jīng)功能評(píng)分。結(jié)果 治療后，治療組總有效率為97.1%。明顯高于對(duì)照組的79.4%（P<0.05）。治療后，治療組腦梗死轉(zhuǎn)化率為11.8%，明顯低于對(duì)照組的41.2%（P<0.05）。治療后，治療組美國國立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分和90 d改良Rankin殘疾量表（mRS）評(píng)分明顯低于對(duì)照組（P<0.05）。結(jié)論 阿加曲班可有效、安全控制頻發(fā)短暫性腦缺血發(fā)作，降低其腦梗死轉(zhuǎn)化率，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To observe the efficacy of argatroban in treatment of frequent transient ischemic attack. Methods Patients (68 cases) with requent transient ischemic attack in Ninghe Hospital from January 2019 to January 2021 were randomly divided into control (34 cases) and treatment (34 cases) groups. Patients in the control group were iv administered with Xuesaitong for injection, 400 mg added into normal saline 500 mL and continuously dropped for more 3 h, once daily. Patients in the treatment group were iv administered with Argatroban Injection, 60 mg added into normal saline 500 mL for 24 h, and they were treated for 2 d, then dropped with 10 mg added into normal saline 250 mL for 5 d, twice daily, the time of each infusion more than 3 h, and the interval time was more 8 h. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, the cerebral infarction transformation and neurological function scores in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 97.1%, which was significantly higher than 79.4% in the control group (P < 0.05). After treatment, the conversion rate of cerebral infarction in the treatment group was 11.8%, which was significantly lower than 41.2% in the control group (P < 0.05). After treatment, the scores of NIHSS and mRS in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Argatroban can effectively and safely control frequent transient ischemic attacks and reduce the conversion rate of cerebral infarction, which has a certain clinical application value.

R971